SUPPLEMENTAL MATERIAL

 Table S1. Behavioral assessment of HDAC2 knockdown on functional recovery from stroke.

	Pre-operation			1	11 d after	stroke		18 d afte	er stroke	25 d after stroke				
		Str	oke		Str	oke		Str	oke		Str	oke		
	Sham	Sham LV-GFPLV-HDAC2-		Sham LV-GFPLV-HDAC2-			Sham	LV-GFP	LV-HDAC2-	Sham LV-GFPLV-HDAC2-				
	shRNA-GFP		shRNA-GFP				s	hRNA-GFP	shRNA-GFF					
	(n =10) (n =13)	(n =13)	(n =10)) (n =13)	(n =13)	(n =10)	(n =13)	(n =13)	(n =10) (n =13)	(n =13)		
Foot faults relative	7.80	8.19	7.50	8.24	28.47	18.40	8.19	25.14	17.43	8.11	23.98	16.22		
to total steps taken	±	±	±	±	±	±	±	±	±	±	±	±		
(%) [forelimb]	0.47	0.43	0.53	0.73	1.81	1.64	0.43	0.89	1.67	0.63	1.30	0.72		
Foot faults relative	1.86	1.78	1.81	1.99	6.65	3.59	1.70	5.91	3.55	1.41	6.28	2.91		
to total steps taken	±	±	±	±	±	±	±	±	±	±	±	±		
(%) [hindlimb]	0.63	0.50	0.50	0.69	0.27	0.60	0.60	0.17	0.84	0.74	0.39	0.67		
Time spent on right	0.57	0.20	0.32	0.24	25.41	16.60	0.87	23.55	15.93	0.77	18.04	10.92		
paw relative to left	±	±	±	±	±	±	±	±	±	±	±	±		
(%)	1.25	1.06	0.95	0.96	2.81	1.54	0.51	2.22	1.82	0.81	2.18	1.54		

Table	S2.	Behavioral	assessment	of	HDAC2	over-expression	on	functional	recovery
from st	troke	2.							

	Pre-operation Sham			1	1 d after	stroke	18 d after stroke Stroke			25 d after stroke		
	Sham	orinactive.	Critical Control	Sham	a _{thactive}	0,40,40 0,4	Sham	alinactive.	0,410,410 0,410,410	Shar	dinactive.	a Hore Co
	(n =10)	マズ (n =13)	√ (n =13)	(n =10	√ 次) (n =13)	√ (n =13)	(n =10	√ 次) (n =13)	√ (n =13)	(n =1	v x 0) (n =13)	(n =13)
Foot faults relative	7.84	7.28	8.06	8.22	18.94	30.06	8.27	16.86	26.73	6.58	14.53	19.59
to total steps taken	±	±	±	±	±	±	±	±	±	±	±	±
(%) [forelimb]	0.71	0.52	0.54	0.75	0.70	1.19	0.65	0.89	1.15	0.62	0.75	0.61
Foot faults relative	1.85	1.68	1.70	1.33	4.24	7.18	1.83	4.31	7.47	1.69	3.99	6.69
to total steps taken	±	±	±	±	±	±	±	±	±	±	±	±
(%) [hindlimb]	0.26	0.38	0.25	0.24	0.26	1.19	0.29	0.83	0.53	0.30	0.28	0.90
Time spent on right	0.01	0.07	0.24	0.27	18.42	26.06	0.03	12.62	20.04	0.05	11.24	16.07
paw relative to left	±	±	±	±	±	±	±	±	±	±	±	±
(%)	0.93	0.70	1.20	0.36	1.56	2.64	1.50	1.33	2.33	0.79	1.60	1.01

	Pre	e-operati	on	11 0	d after st	roke	18	d after s	troke	25	d after st	roke	
		Stro	oke		Stro	ke		Stro	ke		Stro	oke	
WT	Sham	Vehicle	TSA	Sham	Vehicle	TSA	Sham	Vehicle	TSA	Sham	Vehicle	TSA	
	(n = 7)	(n = 7)	(n = 7)	(n = 7)	(n = 7)	(n = 7)	(n = 7)	(n = 7)	(n = 7)	(n = 7)	(n = 7)	(n = 7)	
Foot faults relative	9.14	9.35	8.94	9.45	27.14	19.53	9.70	24.79	17.21	9.14	21.40	15.12	
to total steps taken	±	±	±	±	±	±	±	±	±	±	±	±	
(%) [forelimb]	1.08	0.32	0.45	0.73	1.79	1.49	0.48	1.09	0.62	0.25	0.96	0.53	
Foot faults relative	2.05	2.10	2.01	1.98	6.28	3.84	2.25	5.38	3.33	1.83	5.20	2.75	
to total steps taken	±	±	±	±	±	±	±	±	±	±	±	±	
(%) [hindlimb]	1.06	0.89	0.48	0.25	0.40	0.25	0.50	0.34	0.25	0.60	0.39	0.37	
Time spent on right	0.53	0.24	0.61	1.76	30.10	17.37	0.35	25.76	16.82	0.62	24.44	13.82	
paw relative to left	±	±	±	±	±	±	±	±	±	±	±	±	
(%)	0.20	0.61	0.24	0.79	3.43	1.16	0.13	2.13	0.78	0.55	2.06	1.01	

 Table S3. Behavioral assessment of TSA on functional recovery from stroke in WT

 mice.

Table S4.	Behavioral	assessment	of	TSA	on	functional	recovery	from	stroke	in	Hdac2
CKO mice	2.										

	Pr	e-operati	on	11 0	d after st	roke	18	d after s	troke	25 d after stroke			
		Stro	oke		Stroke			Stro	ke		oke		
Hdac2 CKO	Sham (n = 7)	Vehicle (n = 7)	TSA (n = 7)	Sham (n = 7)	Vehicle (n = 7)	TSA (n = 7)	Sham (n = 7)	Vehicle (n = 7)	TSA (n = 7)	Sham (n = 7)	Vehicle (n = 7)	TSA (n = 7)	
Foot faults relative	9.51	9.01	8.49	9.96	20.05	20.92	8.87	16.62	17.03	9.71	15.84	14.53	
to total steps taken	±	±	±	±	±	±	±	±	±	±	±	±	
(%) [forelimb]	0.60	0.50	0.29	0.32	1.16	0.71	0.27	1.19	1.19	0.53	0.73	0.64	
Foot faults relative	1.72	2.05	1.85	1.90	3.68	3.73	1.92	3.11	3.92	1.98	2.93	3.04	
to total steps taken	±	±	±	±	±	±	±	±	±	±	±	±	
(%) [hindlimb]	0.33	0.40	0.33	0.48	0.36	0.83	0.19	0.47	0.46	0.53	0.38	0.47	
Time spent on right	0.77	1.46	0.61	0.61	14.06	15.66	0.37	15.39	14.01	1.09	14.67	13.58	
paw relative to left	±	±	±	±	±	±	±	±	±	±	±	±	
(%)	0.56	0.70	0.54	0.44	2.64	1.56	0.20	3.04	1.36	0.75	1.54	1.22	

	Pre-operation			11	d after st	roke	18	d after s	troke	25 d after stroke				
		Str	oke		Str	oke		Stro	oke	Stroke				
	Sham (n =10)	Vehicle) (n =13)	SAHA (n =13)	Sham (n =10)	Vehicle (n =13)	SAHA (n =13)	Sham (n =10)	Vehicle (n =13)	SAHA (n =13)	Sham (n =10)	Vehicle (n =13)	SAHA (n =13)		
Foot faults relative	6.69	6.62	7.13	8.29	25.68	18.39	7.63	23.52	17.28	7.25	21.65	16.24		
to total steps taken	±	±	±	±	±	±	±	±	±	±	±	±		
(%) [forelimb]	0.45	0.63	0.58	0.38	1.50	0.75	0.53	1.74	0.64	0.44	1.64	0.91		
Foot faults relative	2.05	1.89	1.78	1.38	8.04	4.05	1.41	7.82	4.12	1.82	7.71	4.29		
to total steps taken	±	±	±	±	±	±	±	±	±	±	±	±		
(%) [hindlimb]	0.39	0.52	0.32	0.59	0.86	0.69	0.58	1.15	0.81	0.54	0.89	1.01		
Time spent on right	0.51	0.12	0.33	0.08	29.92	19.06	0.27	26.14	16.07	0.16	23.05	13.40		
paw relative to left	±	±	±	±	±	±	±	±	±	±	±	±		
(%)	0.99	0.98	0.76	0.98	3.31	3.20	0.85	3.89	1.64	0.62	2.18	1.50		

Table S5. Behavioral assessment of SAHA on functional recovery from stroke.

Figure S1. Scatterplot for correlation between neuroscore and lesion size after stroke



(n = 12, R = 0.863, P < 0.001).

Figure S2. Diagram and immunostaining showing peri-infarct cortex.



(A) The diagram showing the definition of the peri-infarct cortex for immunoblots. (B) Representative images of immunohistochemical labeling of NeuN, a transcription factor that is expressed in mature neurons. Scale bar, 500 μ m. (C) Representative images of immunohistochemical labeling of GFAP, a marker of astrocytes. (D) The merged image from (B) and (C) showing the peri-infarct area. In the peri-infarct cortex, activated astrocytes were radiately distributed. GFAP, glial fibrillary acidic protein.





(A) A representative image showing LV-HDAC2-shRNA-GFP-infected peri-infarct cortex. (B) A high-magnification image from a selected area in leftward image. LV, lentivirus; HDAC2, histone deacetylase 2; shRNA, short hairpin RNA; GFP, green fluorescent protein.

Figure S4. Elimination of HDAC2 protein expression in the cortex is demonstrated by Western analysis.



(A) Immunoblots showing HDAC2 levels in the cortex of HDAC2^{*flox/flox*}-Nestin-Cre and control HDAC2^{*flox/flox*} mice. (B) Bar graph showing cortex HDAC2 level of *Hdac2* CKO mice and WT littermates (n = 3, two-tailed *t test*, ^{***}P < 0.001). HDAC2, histone deacetylase 2; *Hdac2* CKO, *Hdac2* conditional knockout; WT, wild type.

Figure S5. *Hdac2* CKO leads to compensatory up-regulation of HDAC3.



(A) Immunoblots showing HDAC3 levels in the cortex of WT and *Hdac2* CKO mice. (B) Bar graph showing cortex HDAC3 level of *Hdac2* CKO mice and WT littermates (n = 3, two-tailed *t test*, *P < 0.05). *Hdac2* CKO, *Hdac2* conditional knockout; HDAC3, histone deacetylase 3; WT, wild type.

Figure S6. Administration of SAHA during 4-10 d after stroke has no effect on infarct size.



(A) Representative Nissl-stained sections at 11 d after stroke from stroke + vehicle and stroke + SAHA, respectively. (B) Bar graph showing stroke volume from stroke+vehicle and stroke + SAHA, respectively (n = 8, two tailed *t test*, P > 0.05). SAHA, suberoylanilide hydroxamic acid.



Figure S7. HDAC2 knockdown reversed, whereas HDAC2 over-expression further augmented stroke-induced down-regulation of neuroplasticity-related proteins.

(A) Representative immunoblots and (B) Bar graph showing levels of Synapsin and Spinophilin in the peri-infarct cortext after stroke (n = 4, one-way ANOVA, *P < 0.05, ***P < 0.001, LV-GFP vs sham; ##P < 0.01, ###P < 0.001, LV-HDAC2-shRNA-GFP vs LV-GFP; $^{\&}P < 0.05$, $^{\&\&\&}P < 0.001$, Ad-inactive-HDAC2-Flag vs sham; $^{\$}P < 0.05$, Ad-HDAC2-Flag vs Ad-inactive-HDAC2-Flag). HDAC2, histone deacetylase 2; LV, lentivirus; shRNA, short hairpin RNA; GFP, green fluorescent protein; Ad, adenovirus.